Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhythm BiosciencesFRA:0RY +0.95%31 10-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 121 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 826445.45% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Rhythm Biosciences does not have enough data to calculate 10-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Rhythm Biosciences 10-Year RORE % Related Terms
Rhythm Biosciences 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0RY vs TMO, DHR, IDXX: 10-Year RORE % Comparison
For the Diagnostics & Research subindustry, Rhythm Biosciences's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences 10-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.
Rhythm Biosciences (FRA:0RY) has a 10-Year RORE % of 0.00 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #999999 out of 121 companies in the Medical Diagnostics & Research industry.
Is Rhythm Biosciences' 10-Year RORE % too high?
Rhythm Biosciences' current 10-Year RORE % is 0.00. Based on the distribution chart, Rhythm Biosciences ranks #999999 out of 121 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' 10-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #999999 out of 121 companies for 10-Year RORE %. This places Rhythm Biosciences in the lower half of its industry. The industry median 10-Year RORE % is 1.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Diagnostics & Research company?
The median 10-Year RORE % among Medical Diagnostics & Research companies is 1.55, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year RORE % is 1.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current 10-Year RORE % of 0.00. The current 10-Year RORE % is 0.00. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current 10-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
